- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00003854
Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer
A Prognostic Study of Sentinel Node and Bone Marrow Micrometastases in Women With Clinical T1-2 N0 Breast Cancer
RATIONALE: Biopsy of sentinel lymph nodes and bone marrow may improve the ability to detect and determine the extent of cancer.
PURPOSE: Phase III prognostic study of sentinel lymph node metastases and bone marrow metastases in women who have stage I or stage IIA breast cancer.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
OBJECTIVES:
- Estimate the prevalence and evaluate the prognostic significance of sentinel lymph node micrometastases detected by immunohistochemistry in women with stage I or IIA breast cancer.
- Estimate the prevalence and evaluate the prognostic significance of bone marrow micrometastases detected by immunocytochemistry in these patients.
- Evaluate the hazard rate for regional recurrence in women whose sentinel nodes are negative by hematoxylin and eosin (H&E) staining.
- Provide a mechanism for identifying women whose sentinel nodes contain metastases detected by H&E so that these women can be considered as candidates for ACOSOG-Z0011.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Victoria
-
East Melbourne, Victoria, Australien, 8006
- Peter Maccallum Cancer Institute
-
-
-
-
-
Cork, Irland
- Cork University Hospital
-
Dublin, Irland, 4
- St. Vincent'S University Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294-3300
- University of Alabama at Birmingham Comprehensive Cancer Center
-
Mobile, Alabama, Vereinigte Staaten, 36640-0460
- Mobile Infirmary Medical Center
-
Mobile, Alabama, Vereinigte Staaten, 36685
- Providence Hospital - Mobile AL
-
-
Arizona
-
Scottsdale, Arizona, Vereinigte Staaten, 85259
- Mayo Clinic Scottsdale
-
-
Arkansas
-
Fayetteville, Arkansas, Vereinigte Staaten, 72703
- Washington Regional Medical Center
-
Little Rock, Arkansas, Vereinigte Staaten, 72205-5331
- St. Vincent Doctors Doctors Hospital
-
Little Rock, Arkansas, Vereinigte Staaten, 72205-7200
- Baptist Health Medical Center
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90027
- Kaiser Permanente Medical Center - Los Angeles
-
Oakland, California, Vereinigte Staaten, 94609
- Summit Medical Center
-
Orange, California, Vereinigte Staaten, 92868-3849
- St. Joseph Hospital - Orange
-
Pasadena, California, Vereinigte Staaten, 91109-7013
- Huntington Memorial Hospital
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis Cancer Center
-
San Diego, California, Vereinigte Staaten, 92123
- Donald N. Sharp Memorial Community Hospital
-
San Francisco, California, Vereinigte Staaten, 94143-0128
- UCSF Comprehensive Cancer Center
-
Santa Monica, California, Vereinigte Staaten, 90404
- John Wayne Cancer Institute
-
-
Colorado
-
Colorado Springs, Colorado, Vereinigte Staaten, 80909
- Memorial Hospital Cancer Center
-
Denver, Colorado, Vereinigte Staaten, 80010
- University of Colorado Cancer Center
-
-
Connecticut
-
Farmington, Connecticut, Vereinigte Staaten, 06030-3955
- University of Connecticut Health Center
-
-
Delaware
-
Wilmington, Delaware, Vereinigte Staaten, 19899
- CCOP - Christiana Care Health Services
-
-
District of Columbia
-
Washington, District of Columbia, Vereinigte Staaten, 20007
- Lombardi Cancer Center
-
-
Florida
-
Clearwater, Florida, Vereinigte Staaten, 33756
- Morton Plant Mease Health Care
-
Lakeland, Florida, Vereinigte Staaten, 33804
- Lakeland Regional Medical Center
-
Lakeland, Florida, Vereinigte Staaten, 33805
- Watson Clinic
-
Saint Petersburg, Florida, Vereinigte Staaten, 33701
- Bayfront Medical Center
-
Stuart, Florida, Vereinigte Staaten, 34995
- Martin Memorial Cancer Medical Center
-
Tallahassee, Florida, Vereinigte Staaten, 32308
- Tallahassee Memorial HealthCare
-
Tampa, Florida, Vereinigte Staaten, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Decatur, Georgia, Vereinigte Staaten, 30033
- DeKalb Medical Center, Inc.
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96819
- Kaiser Permanente Medical Center
-
Honolulu, Hawaii, Vereinigte Staaten, 96817
- St. Francis Medical Center
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83712
- St. Luke's Regional Medical Center
-
-
Illinois
-
Belleville, Illinois, Vereinigte Staaten, 62220-1998
- St. Elizabeth's Hospital
-
Belleville, Illinois, Vereinigte Staaten, 62226-5399
- Belleville Memorial Hospital
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern University Medical Center
-
Evanston, Illinois, Vereinigte Staaten, 60201
- Evanston Northwestern Health Care
-
Evanston, Illinois, Vereinigte Staaten, 60201
- CCOP - Evanston
-
Evergreen Park, Illinois, Vereinigte Staaten, 60805-2746
- Little Company of Mary Hospital - Evergreen Park
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Loyola University Medical Center
-
-
Indiana
-
Michigan City, Indiana, Vereinigte Staaten, 46360
- Saint Anthony Memorial Health Center - Michigan City Campus
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66160-7357
- University of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40503-9985
- Central Baptist Hospital
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- James Graham Brown Cancer Center
-
Louisville, Kentucky, Vereinigte Staaten, 40202-5070
- Norton Healthcare System
-
-
Louisiana
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70821-2511
- Baton Rouge General Medical Center
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70815
- Woman's Hospital
-
-
Maryland
-
Annapolis, Maryland, Vereinigte Staaten, 21401
- Anne Arundel Medical Center
-
-
Massachusetts
-
Burlington, Massachusetts, Vereinigte Staaten, 01805
- Lahey Clinic - Burlington
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Vereinigte Staaten, 48201-1379
- Barbara Ann Karmanos Cancer Institute
-
Flint, Michigan, Vereinigte Staaten, 48432
- McLaren Regional Cancer Center
-
Grand Blanc, Michigan, Vereinigte Staaten, 48439-8066
- Genesys Regional Medical Center
-
Grand Rapids, Michigan, Vereinigte Staaten, 49546
- Spectrum Health - Butterworth Campus
-
West Bloomfield, Michigan, Vereinigte Staaten, 48322
- Henry Ford Medical Center - West Bloomfield
-
-
Minnesota
-
St. Louis Park, Minnesota, Vereinigte Staaten, 55416
- Park Nicollet Clinic
-
-
Mississippi
-
Keesler AFB, Mississippi, Vereinigte Staaten, 39534-2576
- Keesler Medical Center - Keesler AFB
-
Pascagoula, Mississippi, Vereinigte Staaten, 39581
- Singing River Hospital
-
-
Missouri
-
Columbia, Missouri, Vereinigte Staaten, 65212
- University of Missouri-Columbia Hospital and Clinics
-
Columbia, Missouri, Vereinigte Staaten, 65203
- Ellis Fischel Cancer Center - Columbia
-
Columbia, Missouri, Vereinigte Staaten, 65201
- Columbia Regional Hospital
-
Saint Louis, Missouri, Vereinigte Staaten, 63110
- Barnes-Jewish Hospital
-
Saint Louis, Missouri, Vereinigte Staaten, 63110-2500
- St. Louis University Health Sciences Center
-
Springfield, Missouri, Vereinigte Staaten, 65807-1988
- Lester E. Cox Medical Centers
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756-0002
- Norris Cotton Cancer Center
-
-
New Jersey
-
Mount Holly, New Jersey, Vereinigte Staaten, 08060
- Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital
-
-
New York
-
Brooklyn, New York, Vereinigte Staaten, 11220
- Lutheran Medical Center
-
Buffalo, New York, Vereinigte Staaten, 14263-0001
- Roswell Park Cancer Institute
-
Kingston, New York, Vereinigte Staaten, 12401
- Benedictine Hospital
-
Kingston, New York, Vereinigte Staaten, 12401-4692
- Kingston Hospital
-
New York, New York, Vereinigte Staaten, 10021
- New York Presbyterian Hospital - Cornell Campus
-
New York, New York, Vereinigte Staaten, 10019
- St. Luke's-Roosevelt Hospital Center - Roosevelt Division
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester Medical Center
-
Rochester, New York, Vereinigte Staaten, 14620
- Highland Hospital of Rochester
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Charlotte, North Carolina, Vereinigte Staaten, 28232-2861
- Carolinas Medical Center
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke Comprehensive Cancer Center
-
Durham, North Carolina, Vereinigte Staaten, 27704-2763
- Durham Regional Hospital
-
Fayetteville, North Carolina, Vereinigte Staaten, 28302-2000
- Cape Fear Valley Health System
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 90027
- Tri-Health Good Samaritan Hospital
-
Cleveland, Ohio, Vereinigte Staaten, 44106-5065
- Ireland Cancer Center
-
Columbus, Ohio, Vereinigte Staaten, 43210-1228
- Arthur G. James Cancer Hospital - Ohio State University
-
Toledo, Ohio, Vereinigte Staaten, 43608
- St. Vincent Mercy Medical Center
-
Toledo, Ohio, Vereinigte Staaten, 43606
- Toledo Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18102
- Sacred Heart Hospital
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19111
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15219
- Mercy Hospital of Pittsburgh
-
York, Pennsylvania, Vereinigte Staaten, 17403
- York Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02905
- Women and Infants Hospital of Rhode Island
-
Warwick, Rhode Island, Vereinigte Staaten, 02886
- Kent County Memorial Hospital
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232-6838
- Vanderbilt-Ingram Cancer Center
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Sarah Cannon-Minnie Pearl Cancer Center
-
Nashville, Tennessee, Vereinigte Staaten, 37236
- Baptist Hospital
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78701
- Texas Cancer Center at Brackenridge Hospital
-
Dallas, Texas, Vereinigte Staaten, 75235-9154
- Simmons Cancer Center - Dallas
-
Dallas, Texas, Vereinigte Staaten, 75246
- Baylor University Medical Center
-
Dallas, Texas, Vereinigte Staaten, 75235
- St. Paul University Hospital
-
Dallas, Texas, Vereinigte Staaten, 75235-7786
- Zale Lipshy University Hospital
-
Galveston, Texas, Vereinigte Staaten, 77555-0542
- University of Texas Medical Branch
-
Houston, Texas, Vereinigte Staaten, 77030-4009
- University of Texas - MD Anderson Cancer Center
-
Houston, Texas, Vereinigte Staaten, 77030
- Ben Taub General Hospital
-
Houston, Texas, Vereinigte Staaten, 77030
- Methodist Hospital
-
Lubbock, Texas, Vereinigte Staaten, 79410-1894
- Joe Arrington Cancer Research and Treatment Center
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84132
- Huntsman Cancer Institute
-
Salt Lake City, Utah, Vereinigte Staaten, 84143
- Latter Day Saints Hospital
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- Cancer Center at the University of Virginia
-
Christiansburg, Virginia, Vereinigte Staaten, 24073
- Carilion New River Valley Medical Center
-
Falls Church, Virginia, Vereinigte Staaten, 22042-3300
- INOVA Fairfax Hospital
-
Roanoke, Virginia, Vereinigte Staaten, 24033
- Carilion Health System - Cancer Center of Western Virginia
-
Salem, Virginia, Vereinigte Staaten, 24153
- Columbia Lewis-Gale Medical Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98195-6043
- University of Washington Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53792-6164
- University of Wisconsin Comprehensive Cancer Center
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53201-0342
- Aurora Sinai Medical Center
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Froedtert Memorial Lutheran Hospital
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53215-5166
- St. Luke's Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patient must be female.
- Patient's clinical stage must be I or II (T1 or T2 N0 M0) and the tumor must be amenable to segmental mastectomy (lumpectomy).
- Patient must have a tissue diagnosis of invasive breast carcinoma. Note: A patient can be registered to this study if they have a cytologic diagnosis suggestive of carcinoma from a fine needle aspiration (FNA) of a palpable or non-palpable breast lesion and the investigator believes the breast lesion is clinically suspicious for invasive breast carcinoma.
- The date of the patient's first tissue diagnosis of invasive breast carcinoma or cytologic diagnosis of breast carcinoma must be no more than 60 days prior to SLND.
- The patient who had segmental mastectomy (lumpectomy) performed previously, and is now referred to the local investigator for SLND, is eligible if the lumpectomy was less than or equal to 60 days prior to the SLND. Copies of the operative and pathology reports must be submitted as a part of the registration process.
- Patient must have ECOG/Zubrod status of ≤2, as documented in patient's medical record.
- Patient must be available for follow-up.
The patient with a history of a previous malignancy is eligible for this study as long as the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided that the following criteria are met:
- The patient has undergone potentially curative therapy for all prior malignancies.
- There has been no evidence of any prior malignancies for at least five years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone), and
- The patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies.
- Signed and dated informed consent is obtained prior to patient registration.
- Patients of childbearing potential must have a negative serum or urine pregnancy test within 14 days of beginning study interventions.
- Patient must be able to physically undergo bilateral anterior iliac crest bone marrow aspiration.
Exclusion Criteria:
- Patient is lactating (breastfeeding).
- Patient has been previously treated with chemotherapy, estrogen receptor antagonists (i.e. Tamoxifen) or selective estrogen receptor modulators (SERMs, i.e. Raloxifene) for this invasive breast cancer.
- Patient has a previously placed pre-pectoral breast implant. NOTE: A subpectoral implant is allowed.
- Patient is considered a poor surgical risk due to a non-malignant systemic disease (cardiovascular, renal, etc.), which would preclude the treatment options.
- Patient has concurrent bilateral invasive breast malignancies.
Patient is not able to undergo and does not have access to radiation therapy as describedin Adjuvant Radiation Therapy in the Interventions section of the protocol.
Patients with active connective tissue disorders and those that live too far from a radiation treatment center, for example, would not be eligible.
- Patient has clinically and radiologically identified multi-centric disease that is not amenable to a single lumpectomy.
- Patient has had previous ipsilateral axillary surgery such as excisional biopsy of lymph node(s), treatment of hidradenitis.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Surgery + radiotherapy + adjuvant therapy
Patients undergo bilateral anterior iliac crest bone marrow aspiration to test for presence of micrometastases. Patients then undergo breast-conserving therapy comprising segmental mastectomy and sentinel lymph node dissection (SLND) with planned postoperative whole-breast radiotherapy and systemic adjuvant therapy. The SLND comprises ipsilateral axillary sentinel node identification and histopathology. Patients with no sentinel node identified intraoperatively and patients with sentinel node metastasis identified by hematoxylin and eosin (H&E) who choose not to be registered to ACOSOG-Z0011 undergo axillary lymph node dissection involving removal of at least level I and II nodes. All patients undergo whole-breast radiotherapy (excluding a supraclavicular field) 5 days a week for a maximum of 8 weeks. Patients are followed at 30 days; at 6, 12, 18, 24, 30, and 36 months; and then annually until 10 years after surgery. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Gesamtüberleben
Zeitfenster: Bis zu 10 Jahre
|
Bis zu 10 Jahre
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Krankheitsfreies Überleben
Zeitfenster: Bis zu 10 Jahre
|
Bis zu 10 Jahre
|
|
Axillary recurrence following detection of negative SN with H&E staining in women who did not have an ALND
Zeitfenster: Up to 10 years
|
Up to 10 years
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienstuhl: Armando E. Giuliano, MD, Saint John's Cancer Institute
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Olson JA Jr, McCall LM, Beitsch P, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE; American College of Surgeons Oncology Group Trials Z0010 and Z0011. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol. 2008 Jul 20;26(21):3530-5. doi: 10.1200/JCO.2007.15.5630.
- Hunt KK, Ballman KV, McCall LM, Boughey JC, Mittendorf EA, Cox CE, Whitworth PW, Beitsch PD, Leitch AM, Buchholz TA, Morrow MA, Giuliano AE. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012 Sep;256(3):428-36. doi: 10.1097/SLA.0b013e3182654494.
- Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt KK, McCall LM, Abati A, Cote R. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011 Jul 27;306(4):385-93. doi: 10.1001/jama.2011.1034.
- Wilke LG, Ballman KV, McCall LM, Giuliano AE, Whitworth PW, Blumencranz PW, Reintgen DS, Burak WE, Leitch AM, Hunt KK. Adherence to the National Quality Forum (NQF) breast cancer measures within cancer clinical trials: a review from ACOSOG Z0010. Ann Surg Oncol. 2010 Aug;17(8):1989-94. doi: 10.1245/s10434-010-0980-9. Epub 2010 Mar 23.
- Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE 2nd, Giuliano AE. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006 Apr;13(4):491-500. doi: 10.1245/ASO.2006.05.013. Epub 2006 Mar 2.
- Leitch AM, Beitsch PD, McCall LM, Posther K, Newman LA, Herndon JE 2nd, Hunt KK, Giuliano AE. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Am J Surg. 2005 Oct;190(4):539-42. doi: 10.1016/j.amjsurg.2005.06.024.
- Posther KE, McCall LM, Blumencranz PW, Burak WE Jr, Beitsch PD, Hansen NM, Morrow M, Wilke LG, Herndon JE 2nd, Hunt KK, Giuliano AE. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005 Oct;242(4):593-9; discussion 599-602. doi: 10.1097/01.sla.0000184210.68646.77.
- Katz MS, McCall L, Ballman K, Jagsi R, Haffty BG, Giuliano AE. Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations. Breast Cancer Res Treat. 2020 Apr;180(2):429-436. doi: 10.1007/s10549-020-05555-z. Epub 2020 Feb 10. Erratum In: Breast Cancer Res Treat. 2021 Feb;185(3):891.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- ACOSOG-Z0010
- GUMC-00152
- CDR0000067017 (Registrierungskennung: NCI Physician Data Query)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .